Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “HAND DERMATOSES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 757 records · Page 42Linked to original sources
PubMed1985

Palmoplantar lesions in psoriatic patients and their relation to inverse psoriasis, tinea infection and contact allergy.

One hundred and seven psoriatics with palmoplantar involvement were clinically examined. They were selected from 921 patients filed in 1976 with the diagnosis psoriasis. Fifty per cent of the patients with palmoplantar psoriasis had flexural changes. The frequency of palmar involvement in patients with inverse psoriasis compared to patients with psoriasis vulgaris was increased 5.3 times. Pustulosis palmoplantaris (PPP) in addition to psoriasis was diagnosed in 18 patients (17%). A dermatophyte infection was observed in 1 of 48 patients examined for tinea infection. Positive patch tests were obtained in 8 of 47 patients, 7 of whom had more than one test reaction. The result gives no evidence of tinea infection and contact allergy as important factors in maintaining palmoplantar psoriasis.

Adult↗
PubMed1985

PUVA treatment of chronic eczematous dermatitis of the palms and soles.

Thirty-eight patients were treated with PUVA for chronic eczematous dermatitis of the palms. Twenty (53%) were completely free from lesions when treatment was stopped, and 11 (29%) were improved. Patients who showed healing remained in remission for an average of greater than or equal to 11 months (range 3 weeks to greater than or equal to 36 months). When the rash recurred it was often milder than before PUVA. Sixteen of the 38 patients also had chronic plantar dermatitis; PUVA treatment resulted in complete clearing in 7 (41%), and remission persisted for an average of greater than or equal to 16 months.

Adult↗
PubMed1985

PUVA therapy for palmoplantar pustulosis.

Forty patients suffering from pustulosis palmoplantaris were treated with PUVA therapy. Thirty-six patients had palmar lesions which cleared in 31 cases; in 18 cases after an initial course of 3 sessions of treatment per week during an average period of 10 weeks, and in another 13 only after additional, less frequent continuation of the PUVA therapy. The average total UVA dose at clearing of the palmar lesions was 191 and the final UVA dose 7.3 J/cm2. After 2 years, 9 out of the 31 cases of palmar lesions were still completely healed, and the average duration of remission was greater than or equal to 15 months. For plantar lesions the results of PUVA therapy, using essentially the same procedure, were less satisfactory: healing being obtained in only 5 out of 34 cases. However, for palmar and plantar lesions alike, most patients have reported long-standing improvement from PUVA therapy. A surprisingly high frequency of nausea was noted as a side-effect.

Adolescent↗
PubMed1986

Palmoplantar eruption associated with etretinate therapy.

Five psoriatic patients developed papular lesions of palms and soles, shortly after beginning treatment with etretinate. Histological examination in two cases was insignificant. The lesions disappeared without tapering the dose of etretinate. The fact that lesions appeared and subsided within a short period may explain why this unusual adverse reaction of etretinate therapy has not been reported previously.

Adult↗
PubMed1987

Production of interleukin-2 and interleukin-2 inhibitor in patients with palmoplantar pustulosis.

We studied production of interleukin-2 (IL-2) and IL-2 inhibitor from peripheral blood of patients with palmoplantar pustulosis (PPP). Nineteen patients were divided into two groups: those with and those without arthro-osteitis. Although IL-2 production in both groups of patients was within normal limits, those with arthro-osteitis showed greater fluctuation in relation to the disease activity. The IL-2 production of five PPP patients with arthro-osteitis was greatly enhanced in the inactive stage compared with the active stage. Sera from two patients treated with a combination of etretinate and colchicine contained extremely low levels of IL-2 inhibitory activity. The increased IL-2 production in the inactive stage may be due in part to the depletion of IL-2 inhibitor-producing cells by the treatment.

Adult↗
PubMed1988

Skeletal involvement in pustulosis palmo-plantaris with special reference to the sterno-costo-clavicular joints.

Skeletal scintigraphy was performed in patients with pustulosis palmo-plantaris. There was an increased isotope uptake in the sterno-costo-clavicular area in 16 of 73 patients (22%). The skeletal involvement was further studied by computer tomography showing seven characteristics (including unilaterality) typical of the disease. Clinically, the arthritis is aseptic and benign, and only 9 of 16 patients with a positive scintigraphy complained of juxta-sternal arthralgia.

Adult↗
PubMed1988

Epidermal Langerhans' cells in patients with pustulosis palmoplantaris treated with etretinate or etretinate + methoxsalen photochemotherapy.

Epidermal Langerhans' cells (LC) were studied in patients with pustulosis palmoplantaris (PPP) by utilizing the monoclonal antibodies anti-Leu6 and anti-HLA-DR in combination with an immunoperoxidase technique. In non-pustular areas of the skin lesions in PPP, an increased number of epidermal LC was found compared with control subjects. No change in LC counts was observed following etretinate monotherapy for 2 weeks. Etretinate was then combined with PUVA treatment of one palm/sole with the contralateral side as a non-UVA exposed control. After 6-12 weeks of etretinate + PUVA treatment the PPP had resolved and the number of epidermal dendritic HLA-DR+ and Leu6+ cells had normalized. On the contralateral side, etretinate treatment induced a marked clinical improvement and a reduction of HLA-DR+ cells. The observation of an increased LC population in active PPP and a reduction during clinical improvement indicates a close relationship between LC and the activity of PPP.

Adult↗
PubMed1988

Serum lipid changes during acitretin (etretin) treatment of psoriasis and palmo-plantar pustulosis.

The effects of acitretin (free acid of etretinate) on the serum lipoprotein pattern and on the fat elimination in serum of 8 patients with psoriasis and 4 with palmo-plantar pustulosis were studied. The drug was given for 12 weeks; the average daily dose was 40 mg. Lipoprotein analyses and an intravenous fat tolerance test (IVFTT) were performed on three occasions (before, after 8 weeks' treatment, as well as 8 weeks after the end of the treatment). Acitretin increased the triglyceride concentration of the very low density lipoproteins by about 50% (p less than 0.02) and reduced the cholesterol of the high density lipoproteins significantly (p less than 0.001), leading to an increased low density/high density lipoprotein cholesterol ratio (p less than 0.02). The IVFTT indicated a lowering of the fat elimination capacity. All changes reverted to the original values after an 8-week wash-out period. The data suggest that the effects of acitretin on the lipoprotein metabolism resemble those of etretinate and isotretinoin.

Acitretin↗
PubMed1988

Intra-epidermal accumulation of polymorphonuclear leukocytes in persistent palmoplantar pustulosis during treatment with acitretin.

Six patients with persistent palmoplantar pustulosis were treated with acitretin, and the clinical response was compared with the effect on the intra-epidermal accumulation of polymorphonuclear PMN leukocytes. A prompt improvement of pustule formation and subsequently decreased scaling and erythema was seen in all patients. Following discontinuation of therapy, a relapse occurred within 2 weeks. With dosages of 45 or 55 mg/day, the clinical scores were only slightly better than with 25 or 35 mg/day. In patients using 25 mg acitretin a day, the leukotriene B4-induced intra-epidermal accumulation of polymorphonuclear leukocytes was not affected. However, a dosage of 35 mg/day resulted in a significant inhibition of PMN accumulation, dosages of 45 and 55 mg/day causing an even more pronounced inhibition of this process. Although the effect of different dosages of acitretin is not clearly expressed in the severity scores, the dose-dependent effect on PMN chemotaxis in vivo might be of relevance when combination therapies are considered, in order to achieve a complete clinical clearance.

Acitretin↗
PubMed1989

[Experience in treating patients with rubrophytosis with nizoral].

A total of 201 patients suffering from trichophytosis induced by T. rubrum have been effectively treated with nizoral combined with external management: removal of the nail plates, keratolytic and fungicidal therapy. Treatment with this drug should be preceded by a comprehensive clinical and laboratory examination.

Adolescent↗
PubMed1989

[Onychomycoses and their successful therapy].

Fungus-infected nail material in onychomycoses can be very well removed with a combination of 1% Bifonazol and 40% urea cream, thus eliminating other methods of treatment. It is to be stressed however, that the effectiveness of this therapeutic measure is not only due to the successful galenic and dual combination of these therapeutics, but also requires expert dermatological guidance and consequent cooperation by the affected patient to achieve a satisfactory and permanent result.

Administration, Topical↗
PubMed1989

[The function of the hypophysis-thyroid system in patients with rubromycosis].

Blood plasma thyroxine, triiodothyronine, thyroxine-binding globulin, and thyrotropic hormone have been radioimmunoassayed in 148 patients with rubromycosis. Reduced function of the thyroid has been detected in 39% of patients. Specific antifungal therapy does not essentially influence the function of the hypophyseal-thyroid system.

Adult↗